JUUL Lawsuit Settlement Nets Millions for Schools

Mar.22.2023
JUUL Lawsuit Settlement Nets Millions for Schools
Florida school board approves multi-million dollar settlement from JUUL lawsuit.

On March 21st, according to a report by Fox 13 News, Hillsborough County School Board members in Florida are expected to approve a settlement agreement with JUUL that will include compensation for the school. The funds, which are projected to reach millions of dollars and will be paid over the course of several years, are expected to be approved on Tuesday.


A settlement of $440 million.


In September 2022, the Attorney General of Connecticut announced that JUUL has agreed to pay nearly $440 million to settle over 30 lawsuits from several states concerning their high-nicotine electronic cigarette products. Following this, over 1300 school districts in the United States are currently learning about the settlement amounts they will receive.


To participate in a lawsuit claim, a school district must fulfill two requirements: the school must agree to divide 25% of the compensation with participating lawyers, and the school must provide information about the impact of e-cigarettes in their region.


A series of lawsuits has accused JUUL of using deceptive marketing strategies that target young people and harm their health with nicotine-infused e-cigarettes. The accusations also include school administrators being burdened with financial, time, and resource costs as a result of dealing with student addiction.


Previously, Frederick Hyde, the mayor of Polk County, stated that when school administrators conducted random searches, the item they found most frequently was electronic cigarettes. "Faced with the well-known screening before entering the building, students threw away the most electronic cigarettes in the trash cans in front of the school.


It has been reported that in early March, another Florida-based public school, Orange County, learned that it would receive $5.4 million from the settlement. A member of the Orange County school board stated that they intend to use this money to buy electronic cigarette detectors to protect students. They also plan to offer counseling to students who use e-cigarettes.


JUUL still faces lawsuits to contend with.


Since 2019, JUUL has been maintaining a low profile. It has abandoned all American advertising and removed its fruit and candy flavored e-cigarettes from store shelves.


The FDA took action in June 2022 by issuing a marketing ban on all JUUL products sold in the United States.


Subsequently, JUUL questioned this ruling in court. Afterwards, the FDA conducted a scientific review of the company's technology once again.


According to exclusive information compiled by 2FIRSTS, JUUL has paid a total of $2.6376 billion (approximately 18.2 billion RMB) in settlement funds and is still facing nine independent lawsuits from other states. Additionally, the company is also facing hundreds of individual lawsuits brought forth by teenagers and others.


Related reading:


JUUL has paid $18.2 billion in settlements as part of its effort to resolve ongoing legal issues. This article lists the settlement amounts and conditions in various states.


The American brand Juul will pay $440 million to reach a settlement with various states.


A US district court has approved a $255 million settlement for a class-action lawsuit against Juul prior to the start of the trial.


E-cigarette company JUUL has paid out $1.7 billion in settlements, following lawsuits from 34 different US states.


References:


Hillsborough County schools may be awarded millions of dollars as a result of a lawsuit filed against JUUL.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Special Report | Vape bans and tougher rules: the South Caucasus takes different paths
Azerbaijan's sweeping e-cigarette ban has raised concerns over enforcement errors and the emergence of illicit sales, while neighboring Armenia is tightening technical rules and preparing higher excise taxes. Georgia, meanwhile, has resisted calls for broader vape restrictions and introduced preferential taxes for some domestically produced cigarettes. The divergent approaches across the South Caucasus highlight a regional policy dilemma: how to curb nicotine use and protect public health without encouraging black markets or creating unintended economic consequences for businesses and consumers.
Nov.03
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25